Welcome to our dedicated page for Dynavax Technologies Corporation news (Ticker: DVAX), a resource for investors and traders seeking the latest updates and insights on Dynavax Technologies Corporation stock.
Dynavax Technologies Corporation (Nasdaq: DVAX) is a prominent clinical-stage biopharmaceutical firm dedicated to developing innovative vaccines targeting infectious and inflammatory diseases, as well as cancer. With its headquarters in Emeryville, California, the company is renowned for leveraging the body's innate and adaptive immune responses through its proprietary Toll-like Receptor Immune Modulation Platform technology.
Core Products and Clinical Pipeline:
- HEPLISAV-B®: Approved in the U.S., EU, and Great Britain, HEPLISAV-B is the first and only adult hepatitis B vaccine that allows series completion with just two doses in one month. It continues to show strong market expansion and revenue growth.
- CpG 1018® Adjuvant: An essential component in multiple adjuvanted COVID-19 vaccines, this adjuvant enhances the immune response.
- Shingles Vaccine Program (Z-1018): In development for preventing shingles in adults aged 50 and older, promising robust immune responses.
- Tdap Vaccine Program (Tdap-1018): Focused on active booster immunization against tetanus, diphtheria, and pertussis.
- Plague Vaccine Program (DV2-PLG-01): In Phase 2 clinical trials, this program is fully funded by the U.S. Department of Defense.
Recent Achievements and Financial Highlights:
- Dynavax reported record revenue growth for HEPLISAV-B in 2023, capturing significant market share in the adult hepatitis B vaccine sector.
- As of December 31, 2023, the company had cash, cash equivalents, and marketable securities worth $742.3 million, underpinning its strong financial foundation.
- For the first quarter of 2024, Dynavax's net loss was reduced compared to the same period in 2023, due to improved operational efficiencies and strategic market initiatives.
Strategic Partnerships:
Collaborations with global biopharmaceutical companies, including AstraZeneca in Europe, further strengthen Dynavax's market position and broaden its product reach.
For detailed financial information and ongoing updates, investors can access the company's Events & Presentations page on their official website.
Dynavax Technologies Corporation (Nasdaq: DVAX) will participate in several upcoming investor conferences, showcasing its commitment to vaccine development. Key presentations include the 2021 Cantor Virtual Global Healthcare Conference on September 30 at 12:00 p.m. E.T., the Guggenheim 2nd Annual Vaccine and Infectious Disease Conference on October 5 at 12:00 p.m. E.T., and the H.C. Wainwright 2nd Hepatitis B Virus Virtual Conference on October 13 at 12:00 p.m. E.T.. All events will be available via live webcast on their website's 'Events & Presentations' page.
On September 22, 2021, Dynavax Technologies (Nasdaq: DVAX) announced positive results from Clover Biopharmaceuticals' Phase 2/3 SPECTRA trial for their COVID-19 vaccine candidate, SCB-2019, adjuvanted with Dynavax's CpG 1018. The trial, involving over 30,000 participants, demonstrated 100% efficacy against severe COVID-19 and 84% against moderate-to-severe cases, achieving a 79% efficacy against the Delta variant. The vaccine showed a favorable safety profile, with adverse events balanced between vaccine and placebo groups. Clover plans to seek regulatory approvals in Q4 2021, potentially launching the vaccine by year-end.
Dynavax Technologies (Nasdaq: DVAX) announced that Valneva SE received a termination notice from the UK government regarding its COVID-19 vaccine supply agreement for VLA2001. Despite this, Valneva plans to continue clinical trials for VLA2001, with results expected in Q4 2021. Dynavax reiterated a potential revenue opportunity of $300-$400 million for its CpG 1018 adjuvant in 2021, contingent upon ongoing partnerships. There are concerns regarding the impact on Dynavax if Valneva cancels any purchase orders for CpG 1018, but no cancellations have occurred yet.
Dynavax Technologies Corporation (Nasdaq: DVAX) announces that CEO Ryan Spencer will present at the H.C. Wainwright 23rd Annual Global Investment Conference, scheduled for September 13-15, 2021.
The on-demand presentation will be accessible starting September 13, 2021, at 7:00 a.m. E.T. via the Company's Investors section. Dynavax focuses on the development and commercialization of vaccines, including its first product, HEPLISAV-B®, for Hepatitis B prevention.
Dynavax Technologies Corporation (Nasdaq: DVAX) announced the granting of nonstatutory stock options for 224,000 shares to 8 new employees as an inducement for their employment. The options, priced at $19.00 per share, match the closing stock price on the grant date, September 1, 2021. The options vest over three years, with one-third vesting on the first anniversary and the remainder vesting in monthly increments. This grant complies with Nasdaq Listing Rule 5635(c)(4) and follows the company's 2021 Inducement Award Plan.
Medigen Vaccine Biologics Corporation (MVC) and Dynavax Technologies Corporation (Nasdaq: DVAX) announced the rollout of MVC-COV1901, a COVID-19 vaccine, with an initial distribution to approximately 600,000 people in Taiwan. MVC recently received emergency use authorization from the Taiwan FDA for its two-dose vaccine, which utilizes Dynavax's CpG 1018 adjuvant. The vaccine showed promising safety and efficacy in clinical trials. MVC's CEO highlighted the importance of serving Taiwan during the pandemic, while Dynavax's CEO expressed hopes for further approvals of vaccines using their adjuvant.
Dynavax Technologies (DVAX) reported Q2 2021 financial results showing significant growth. Total revenue reached $52.8 million, up from $2.7 million in Q2 2020. HEPLISAV-B net revenue was a record $13.7 million, while CpG 1018 contributed $39 million. The company announced a commercial supply agreement with Biological E for its COVID-19 vaccine candidate. Dynavax also increased its cash reserves to $345.8 million. The CDC is set to vote on a universal hepatitis B recommendation in October 2021.
Dynavax Technologies (Nasdaq: DVAX) announced on August 3, 2021, the granting of stock options to purchase 438,000 shares to 44 new employees. The options, granted on August 2, 2021, have an exercise price of $9.45 per share, aligning with the closing stock price on that date. Each option has a 7-year term and vests over three years, with one-third vesting after one year. This action complies with Nasdaq Listing Rule 5635(c)(4) aimed at incentivizing new hires.
Dynavax Technologies Corporation (NASDAQ: DVAX) is set to report its second quarter 2021 financial results on August 4, 2021, following the close of U.S. markets. A conference call will occur the same day at 4:30 p.m. ET. The company, known for its HEPLISAV-B® Hepatitis B vaccine, continues to develop novel vaccines and adjuvants, including collaborations for COVID-19 and other significant vaccines. The live webcast will be available on their investors’ website, with replay options for 30 days.
Dynavax Technologies (DVAX) announced a commercial supply agreement with Biological E. Limited for its CpG 1018 adjuvant, aimed at enhancing BE's COVID-19 vaccine candidate, CORBEVAX™. The agreement extends through 2022, covering doses manufactured under prior funding from the Coalition for Epidemic Preparedness Innovations (CEPI). In June 2021, India's Ministry of Health secured 300 million doses of CORBEVAX™. Ryan Spencer, CEO of Dynavax, expressed pride in the collaboration, while BE's Managing Director emphasized the vaccine's potential in combating the pandemic.
FAQ
What is the current stock price of Dynavax Technologies Corporation (DVAX)?
What is the market cap of Dynavax Technologies Corporation (DVAX)?
What is Dynavax Technologies Corporation known for?
What are the key products of Dynavax?
What is HEPLISAV-B®?
What is the significance of the CpG 1018® adjuvant?
Who are Dynavax's key partners?
What are the recent financial highlights of Dynavax?
What is the clinical pipeline focus of Dynavax?
How does Dynavax plan to sustain its growth?
How can investors get updates on Dynavax?
What are the most common adverse reactions to HEPLISAV-B?
